Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CADLNASDAQ:CLSDNASDAQ:GOSSNASDAQ:ITOS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCADLCandel Therapeutics$8.09+1.0%$8.24$1.34▼$14.60$262.73M-1.292.65 million shs903,471 shsCLSDClearside Biomedical$0.87+2.1%$0.96$0.77▼$1.93$65.99M2.1372,428 shs79,541 shsGOSSGossamer Bio$1.34+9.8%$1.11$0.50▼$1.56$303.65M1.861.55 million shs2.01 million shsITOSiTeos Therapeutics$7.52+6.5%$7.50$6.67▼$18.75$287.22M1.38453,291 shs671,594 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCADLCandel Therapeutics-2.32%+1.65%-7.51%+3.35%+376.79%CLSDClearside Biomedical-3.17%+6.49%-24.61%-15.65%-57.83%GOSSGossamer Bio+6.09%+7.96%+15.09%+71.20%-8.96%ITOSiTeos Therapeutics+1.58%+3.07%-6.98%-14.94%-40.82%Remove AdsMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCADLCandel Therapeutics3.2408 of 5 stars3.52.00.00.04.03.30.6CLSDClearside Biomedical2.8369 of 5 stars3.55.00.00.02.41.70.0GOSSGossamer Bio4.2303 of 5 stars3.54.00.04.72.71.70.0ITOSiTeos Therapeutics2.2968 of 5 stars3.51.00.00.02.62.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCADLCandel Therapeutics 3.00Buy$21.00159.58% UpsideCLSDClearside Biomedical 3.00Buy$5.33512.96% UpsideGOSSGossamer Bio 3.00Buy$9.20586.57% UpsideITOSiTeos Therapeutics 3.00Buy$25.75242.42% UpsideCurrent Analyst Ratings BreakdownLatest CLSD, CADL, ITOS, and GOSS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/6/2025CLSDClearside BiomedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/6/2025CLSDClearside BiomedicalNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/6/2025ITOSiTeos TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$19.00 ➝ $17.003/6/2025ITOSiTeos TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$22.00 ➝ $15.003/6/2025ITOSiTeos TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$46.00 ➝ $46.003/5/2025ITOSiTeos TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$25.002/26/2025CADLCandel TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $25.002/26/2025CADLCandel TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.002/20/2025CADLCandel TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$25.002/19/2025CADLCandel TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$20.002/7/2025CADLCandel TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.00(Data available from 3/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCADLCandel Therapeutics$120K2,189.42N/AN/A$0.44 per share18.39CLSDClearside Biomedical$7.70M8.57N/AN/A($0.25) per share-3.48GOSSGossamer Bio$105.32M2.88N/AN/A$0.28 per share4.79ITOSiTeos Therapeutics$35M8.21N/AN/A$16.08 per share0.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCADLCandel Therapeutics-$37.94M-$1.73N/AN/AN/AN/A-629.29%-173.39%3/27/2025 (Estimated)CLSDClearside Biomedical-$32.49M-$0.45N/AN/AN/A-413.83%N/A-92.90%5/7/2025 (Estimated)GOSSGossamer Bio-$179.82M-$0.32N/AN/AN/AN/A-127.28%-22.12%5/5/2025 (Estimated)ITOSiTeos Therapeutics-$112.64M-$3.31N/AN/AN/AN/A-20.11%-17.50%5/9/2025 (Estimated)Latest CLSD, CADL, ITOS, and GOSS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2025N/ACADLCandel Therapeutics-$0.23N/AN/AN/AN/AN/A3/5/2025Q4 2024ITOSiTeos Therapeutics-$1.14-$1.01+$0.13-$1.01N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCADLCandel TherapeuticsN/AN/AN/AN/AN/ACLSDClearside BiomedicalN/AN/AN/AN/AN/AGOSSGossamer BioN/AN/AN/AN/AN/AITOSiTeos TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCADLCandel TherapeuticsN/A1.181.18CLSDClearside BiomedicalN/A4.494.49GOSSGossamer Bio3.646.746.74ITOSiTeos TherapeuticsN/A14.8014.80Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCADLCandel Therapeutics13.93%CLSDClearside Biomedical18.75%GOSSGossamer Bio81.23%ITOSiTeos Therapeutics97.16%Insider OwnershipCompanyInsider OwnershipCADLCandel Therapeutics41.60%CLSDClearside Biomedical9.20%GOSSGossamer Bio5.00%ITOSiTeos Therapeutics12.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCADLCandel Therapeutics6032.48 million18.97 millionOptionableCLSDClearside Biomedical3075.84 million68.87 millionOptionableGOSSGossamer Bio180226.60 million215.27 millionOptionableITOSiTeos Therapeutics9038.19 million31.97 millionOptionableCLSD, CADL, ITOS, and GOSS HeadlinesRecent News About These CompaniesHC Wainwright Expects Higher Earnings for iTeos TherapeuticsMarch 11 at 1:33 AM | americanbankingnews.comQ1 EPS Estimates for iTeos Therapeutics Raised by WedbushMarch 11 at 1:33 AM | americanbankingnews.comHC Wainwright Issues Optimistic Estimate for ITOS EarningsMarch 10 at 1:31 AM | marketbeat.comResearch Analysts Offer Predictions for ITOS Q1 EarningsMarch 10 at 1:31 AM | marketbeat.comHC Wainwright Reaffirms Buy Rating for iTeos Therapeutics (NASDAQ:ITOS)March 9 at 5:07 AM | americanbankingnews.comWells Fargo & Company Cuts iTeos Therapeutics (NASDAQ:ITOS) Price Target to $17.00March 9 at 4:29 AM | americanbankingnews.comFY2029 Earnings Estimate for ITOS Issued By HC WainwrightMarch 8, 2025 | marketbeat.comJPMorgan Chase & Co. Has Lowered Expectations for iTeos Therapeutics (NASDAQ:ITOS) Stock PriceMarch 8, 2025 | americanbankingnews.comiTeos Therapeutics' (ITOS) "Outperform" Rating Reiterated at WedbushMarch 8, 2025 | americanbankingnews.comWells Fargo & Company Has Lowered Expectations for iTeos Therapeutics (NASDAQ:ITOS) Stock PriceMarch 7, 2025 | marketbeat.comiTeos Therapeutics (NASDAQ:ITOS) Given New $15.00 Price Target at JPMorgan Chase & Co.March 7, 2025 | marketbeat.comiTeos Therapeutics (NASDAQ:ITOS) Receives Buy Rating from HC WainwrightMarch 7, 2025 | marketbeat.comiTeos Therapeutics price target lowered to $17 from $19 at Wells FargoMarch 7, 2025 | markets.businessinsider.comiTeos Therapeutics (NASDAQ:ITOS) Receives Outperform Rating from WedbushMarch 6, 2025 | marketbeat.comiTeos Therapeutics Full Year 2024 Earnings: In Line With ExpectationsMarch 6, 2025 | finance.yahoo.comiTeos Therapeutics (NASDAQ:ITOS) Announces Quarterly Earnings ResultsMarch 6, 2025 | marketbeat.comiTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdatesMarch 5, 2025 | globenewswire.comiTeos Therapeutics: Decimated By Collateral Events, Good Chances Of Success NeverthelessFebruary 27, 2025 | seekingalpha.comiTeos Therapeutics (ITOS) to Release Earnings on WednesdayFebruary 26, 2025 | marketbeat.comiTeos Therapeutics, Inc. (NASDAQ:ITOS) Short Interest UpdateFebruary 17, 2025 | marketbeat.comPeapod Lane Capital LLC Takes Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS)February 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLSD, CADL, ITOS, and GOSS Company DescriptionsCandel Therapeutics NASDAQ:CADL$8.09 +0.08 (+1.00%) Closing price 04:00 PM EasternExtended Trading$7.98 -0.11 (-1.36%) As of 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.Clearside Biomedical NASDAQ:CLSD$0.87 +0.02 (+2.14%) Closing price 04:00 PM EasternExtended Trading$0.89 +0.02 (+2.40%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.Gossamer Bio NASDAQ:GOSS$1.34 +0.12 (+9.84%) Closing price 04:00 PM EasternExtended Trading$1.37 +0.03 (+2.24%) As of 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.iTeos Therapeutics NASDAQ:ITOS$7.51 +0.45 (+6.37%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ramaco Resources Pins Hopes on Coal's Untapped Potential Beyond a Market Correction, Moves to Make Now NVIDIA Stock Remains Stunningly Undervalued—Here’s Why Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy 3 Stocks Institutions Are Quietly Dumping Marvell’s 40% Drop Presents a Compelling Buying Opportunity These 3 Dividend Stocks Jumped 15% in a Month—More to Come? Why Wayfair Stock May Be a Hidden Gem for Value Investors Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
